Enanta Pharmaceuticals Partners its Lead HCV NS5A Inhibitor with Novartis
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 2 (Table of Contents)
Published: 27 Feb-2012
DOI: 10.3833/pdr.v2012.i2.1689 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a potential US$440 M deal, Novartis has gained a global licence to EDP-239, Enanta Pharmaceuticals’ lead preclinical development candidate from its NS5A hepatitis C virus (HCV) inhibitor programme...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS